Physician profile
Kai C Lee
NPI 1720166556
$4,941.80
in general payments reported to CMS, 2019-2025
50 companies · $1,081 in 2025
The $1,081 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $461 · 2021: $668 · 2022: $436 · 2023: $731 · 2024: $1,100 · 2025: $1,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,802 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,801.83 |
| Education | $110.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $765.98 | 2021-2025 | |
| Lilly USA, LLC | $316.56 | 2019-2025 | Kisunla, Amyvid |
| Teva Pharmaceuticals USA, INC. | $290.66 | 2019-2025 | Austedo Xr, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $287.46 | 2019-2025 | Ultomiris |
| Biogen, INC. | $273.53 | 2019-2024 | Vumerity, Tysabri, Avonex |
| Allergan, INC. | $224.47 | 2019-2022 | |
| Ucb, INC. | $211.67 | 2023-2025 | Zilbrysq, Nayzilam, Briviact |
| Merz Pharmaceuticals, LLC | $199.03 | 2022-2025 | Xeomin, Inbrija |
| Novartis Pharmaceuticals Corporation | $183.01 | 2019-2025 | |
| Kyowa Kirin, INC. | $180.29 | 2020-2025 | Nourianz |
| Neurocrine Biosciences, INC. | $175.21 | 2020-2025 | |
| Genentech USA, INC. | $151.66 | 2022-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Amneal Pharmaceuticals LLC | $110.65 | 2019-2025 | Crexont, Rytary |
| Csl Behring | $82.76 | 2019-2022 | |
| Tanabe Pharma America, INC. | $81.82 | 2023-2025 | Radicava |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kai Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.